Status:
UNKNOWN
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Lead Sponsor:
Third Military Medical University
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether sunitinib is effecti...
Detailed Description
OBJECTIVES: Primary * To investigate the effect of sunitinib malate on the progression-free survival of patients with stage IIIB or IV non-small cell lung cancer Secondary * To evaluate the toxicity...
Eligibility Criteria
Inclusion
- No evidence of symptomatic or untreated brain metastases, spinal cord compression, or carcinomatous meningitis
- Histologically or cytologically confirmed primary non-small cell lung cancer who have stable or responding disease after prior treatment with 3-6 courses of platinum -based therapy
- Not a candidate for combined modality therapy
- No cavitary lesions
Exclusion
- Evidence of symptomatic or untreated brain metastases, spinal cord compression, or carcinomatous meningitis
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01210053
Start Date
September 1 2010
End Date
March 1 2012
Last Update
September 28 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Chongqing, Chongqing Municipality, China, 400042